New hope for stomach cancer patients with abdominal spread: experimental drug combo enters trial

NCT ID NCT07384234

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether adding an experimental immunotherapy drug called SHR-1701 to standard chemotherapy can help people with stomach cancer that has spread to the lining of the abdomen. The study will enroll 60 adults and compare two different chemotherapy combinations, with or without SHR-1701. The main goal is to see if the treatment improves survival over two years and whether it can make the cancer removable by surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1701 (an experimental immunotherapy drug) combined with chemotherapy drugs (paclitaxel, S-1, capecitabine, oxaliplatin)
What this could lead to: If successful, this could offer a new treatment option for people with stomach cancer that has spread to the abdomen, potentially improving survival and making surgery possible.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results are preliminary. The combination may cause significant side effects, and the experimental drug SHR-1701 may not improve outcomes over standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Changhai Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.